Atrium Therapeutics Q2 FY26 net loss widens to $20.19 million; revenue falls to $3 million

• Atrium Therapeutics posted a Q2 net loss of $20.19 million, widening from $12.88 million a year earlier.
• Collaboration revenue slipped 21.9% to $3 million, while R&D expense rose 15.4% to $15.34 million.
• G&A expense more than doubled to $10.28 million, reflecting employee-related costs, professional fees, and support for expanded operations.
• Cash, cash equivalents, and short-term investments totaled $263.9 million at June 30; it expects funding through mid-2028 including a $15 million BMS milestone.
• FDA cleared the IND for ATR 1072; Atrium launched the Corventis Phase 1/2 trial in PRKAG2 syndrome with first enrollment expected by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA26302) on August 13, 2026, and is solely responsible for the information contained therein.